|
|
|
|
|
|
Sponsored by: |
Bayer |
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00537836 |
The primary goal of the planned study is to investigate the efficacy and safety of ZK 283197 in the dosage of 2 and 3 mg ingested once daily during a period of 8 weeks for the treatment of hot flushes. In order to be able to assess the efficacy of the test substance, this is compared with the efficacy of 1 mg Estradiol and placebo. The comparator Estradiol is a certified hormone preparation, which is already used for the treatment of hot flushes as standard treatment. After passing the screening, volunteers will start with a run-in phase followed by a 8 weeks treatment and a follow-up phase. 112 postmenopausal women with hot flushes and without relevant prior diseases will participate in three European countries (2 study sites in Germany, 1 study site in Great Britain and 1 study site in The Netherlands) in this study.
Condition | Intervention | Phase |
Vasomotor System |
Drug: ZK 283197 Drug: Placebo Drug: 17ß-estradiol |
Phase II |
Drug Information available for: | Depogen Estradiol Estradiol 3-benzoate Estradiol acetate Estradiol cypionate Estradiol dipropionate Estradiol valerate Polyestradiol phosphate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double- Blind, Randomized, Placebo and Active Controlled, Multi-Center Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-Estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes. |
Estimated Enrollment: | 112 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | January 2009 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
Arm 1: Experimental |
Drug: ZK 283197
3 mg ZK 283197, once daily p.o. over 8 weeks (n = 36)
|
Arm 2: Placebo Comparator |
Drug: Placebo
Placebo, once daily p.o. over 8 weeks (n = 36)
|
Arm 3: Experimental |
Drug: ZK 283197
2 mg ZK 283197, once daily p.o. over 8 weeks (n = 20)
|
Arm 4: Active Comparator |
Drug: 17ß-estradiol
1 mg 17ß-estradiol, once daily p.o. over 8 weeks (n = 20)
|
Ages Eligible for Study: | 45 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Clinical Trials Contact | clinical-trials-contact@bayerhealthcare.com | |
Contact: For trial location information (Phone Menu Options "3" or "4") | (ex US:+1)1-888-84-22937 |
Germany | |||||
Recruiting | |||||
Berlin, Germany, 13342 | |||||
Recruiting | |||||
Berlin, Germany, 10115 | |||||
Netherlands | |||||
Recruiting | |||||
Groningen, Netherlands, 9713 GZ | |||||
United Kingdom, Cambridgeshire | |||||
Recruiting | |||||
Cambridge, Cambridgeshire, United Kingdom, CB23 2TN |
Bayer |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Schering Pharma AG ( Therapeutic Area Head ) |
Study ID Numbers: | 91544, EudraCT-No.: 2007-001791-36, 310781 |
First Received: | September 28, 2007 |
Last Updated: | September 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00537836 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; United States: Institutional Review Board |
|
|
|
|
|